Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 3, 2009, Pages 350-356

  Markowitz, Martin ^a   Nguyen, Bach Yen ^b   Gotuzzo, Eduardo ^c   Mendo, Fernando ^d   Ratanasuwan, Winai ^e   Kovacs, Colin ^f   Prada, Guillermo ^g   Morales Ramirez, Javier O ^h   Crumpacker, Clyde S ⁱ   Isaacs, Robin D ^b   Campbell, Havilland ^b   Strohmaier, Kim M ^b   Wan, Hong ^b   Danovich, Robert M ^b   Teppler, Hedy ^b  

^a AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Cayetano Heredia National Hospital   (Peru)

^d HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

^e MAHIDOL UNIVERSITY   (Thailand)

^f Canadian Immunodeficiency Research Collaborative   (Canada)

^g Fundacion Santafe de Bogota   (Colombia)

^h Clinical Research Puerto Rico Inc   (Puerto Rico)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Antiretroviral therapy; HIV 1; Integrase inhibitor; MK 0518; Raltegravir

Indexed keywords

ANTILIPEMIC AGENT; EFAVIRENZ; RALTEGRAVIR; TENOFOVIR DISOPROXIL PLUS LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS RNA;

ABNORMAL DREAMING; ABNORMAL LABORATORY RESULT; ANXIETY; ARTICLE; ATTENTION DISTURBANCE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FLATULENCE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INSOMNIA; LETHARGY; MAJOR CLINICAL STUDY; MALAISE; MONOTHERAPY; MULTICENTER STUDY; MYOPATHY; MYOSITIS; NAUSEA; NIGHTMARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS RESISTANCE; VOMITING;

ANTI-HIV AGENTS; BENZOXAZINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; PYRROLIDINONES;

EID: 70350558421     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b064b0     Document Type: Article

References (12)

1. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000; 287:646-650.
2. Grinsztejn B, Nguyen B-Y, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet. 2007;369:1261-1269.
3. Steigbigel RT, Cooper, DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. NEngJMed. 2008;359: 339-354.
4. Cooper D, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Eng J Med. 2008; 359:355-365.
5. Markowitz M, Nguyen B-Y, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a48-week controlled study. JAcquirImmuneDefic Syndr. 2007; 46:125-133.
6. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43: 509-515.
7. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-226.
8. Bristol-Myers Squibb, Princeton, NJ. Prescribing information for SUSTI-VA® (efavirenz) capsules and tablets [package insert]. January 2007.
9. Lennox J, DeJesus E, Lazzarin A, et al. STARTMRK, a phase III study of the safety & efficacy of raltegravir (RAL)-based vs efavirenz (EFV)-based combination therapy in treatment-naive HIV-infected patients. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008; Washington, DC. Abstract #H-896a.
10. Gallant JE, Staszewski S, Posniak A, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
11. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535-540.
12. Merck & Co Inc., Whitehouse Station NJ. Prescribing information for ISENTRESS (raltegravir) tablets [package insert]. October 2007.